<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Chemother Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Chemother. Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Cancer Chemotherapy and Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0344-5704</issn><issn pub-type="epub">1432-0843</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7125253</article-id><article-id pub-id-type="pmcid-ver">PMC7125253.1</article-id><article-id pub-id-type="pmcaid">7125253</article-id><article-id pub-id-type="pmcaiid">7125253</article-id><article-id pub-id-type="pmid">32152679</article-id><article-id pub-id-type="doi">10.1007/s00280-019-04028-5</article-id><article-id pub-id-type="publisher-id">4028</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic&#8211;pharmacodynamic model in gastrointestinal cancer patients</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7003-5300</contrib-id><name name-style="western"><surname>Arshad</surname><given-names initials="U">Usman</given-names></name><address><email>arshad_u@outlook.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Ploylearmsaeng</surname><given-names initials="SA">Su-arpa</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Karlsson</surname><given-names initials="MO">Mats O.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Doroshyenko</surname><given-names initials="O">Oxana</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Langer</surname><given-names initials="D">Dorothee</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sch&#246;mig</surname><given-names initials="E">Edgar</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kunze</surname><given-names initials="S">Sabine</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>G&#252;ner</surname><given-names initials="SA">Semih A.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Skripnichenko</surname><given-names initials="R">Roman</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ullah</surname><given-names initials="S">Sami</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jaehde</surname><given-names initials="U">Ulrich</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fuhr</surname><given-names initials="U">Uwe</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Jetter</surname><given-names initials="A">Alexander</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Taubert</surname><given-names initials="M">Max</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.6190.e</institution-id><institution-id institution-id-type="ISNI">0000 0000 8580 3777</institution-id><institution>Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, </institution><institution>University of Cologne, </institution></institution-wrap>Cologne, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.8993.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9457</institution-id><institution>Department of Pharmaceutical Biosciences, </institution><institution>Uppsala University, </institution></institution-wrap>Uppsala, Sweden </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.411097.a</institution-id><institution-id institution-id-type="ISNI">0000 0000 8852 305X</institution-id><institution>Department of Radiotherapy, </institution><institution>University Hospital Cologne, </institution></institution-wrap>Cologne, Germany </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.10388.32</institution-id><institution-id institution-id-type="ISNI">0000 0001 2240 3300</institution-id><institution>Institute of Pharmacy, Clinical Pharmacy, </institution><institution>University of Bonn, </institution></institution-wrap>Bonn, Germany </aff><aff id="Aff5"><label>5</label>Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland </aff></contrib-group><pub-date pub-type="epub"><day>9</day><month>3</month><year>2020</year></pub-date><pub-date pub-type="ppub"><year>2020</year></pub-date><volume>85</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">355333</issue-id><fpage>711</fpage><lpage>722</lpage><history><date date-type="received"><day>4</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>31</day><month>12</month><year>2019</year></date></history><pub-history><event event-type="pmc-release"><date><day>09</day><month>03</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>06</day><month>04</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-23 04:25:14.513"><day>23</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="280_2019_Article_4028.pdf"/><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">To describe 5-fluorouracil (5FU) pharmacokinetics, myelotoxicity and respective covariates using a simultaneous nonlinear mixed effect modelling approach.</p></sec><sec><title>Methods</title><p id="Par2">Thirty patients with gastrointestinal cancer received 5FU 650 or 1000&#160;mg/m<sup>2</sup>/day as 5-day continuous venous infusion (14 of whom also received cisplatin 20&#160;mg/m<sup>2</sup>/day). 5FU and 5-fluoro-5,6-dihydrouracil (5FUH2) plasma concentrations were described by a pharmacokinetic model using NONMEM. Absolute leukocyte counts were described by a semi-mechanistic myelosuppression model. Covariate relationships were evaluated to explain the possible sources of variability in 5FU pharmacokinetics and pharmacodynamics.</p></sec><sec><title>Results</title><p id="Par3">Total clearance of 5FU correlated with body surface area (BSA). Population estimate for total clearance was 249 L/h. Clearances of 5FU and 5FUH2 fractionally changed by 77%/m<sup>2</sup> difference from the median BSA. 5FU central and peripheral volumes of distribution were 5.56 L and 28.5 L, respectively. Estimated 5FUH2 clearance and volume of distribution were 121 L/h and 96.7 L, respectively. Baseline leukocyte count of 6.86&#8201;&#215;&#8201;10<sup>9</sup>/L, as well as mean leukocyte transit time of 281&#160;h accounting for time delay between proliferating and circulating cells, was estimated. The relationship between 5FU plasma concentrations and absolute leukocyte count was found to be linear. A higher degree of myelosuppression was attributed to combination therapy (slope&#8201;=&#8201;2.82 L/mg) with cisplatin as compared to 5FU monotherapy (slope&#8201;=&#8201;1.17 L/mg).</p></sec><sec><title>Conclusions</title><p id="Par4">BSA should be taken into account for predicting 5FU exposure. Myelosuppression was influenced by 5FU exposure and concomitant administration of cisplatin.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1007/s00280-019-04028-5) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>5-Fluorouracil</kwd><kwd>Pharmacokinetics</kwd><kwd>Pharmacodynamics</kwd><kwd>Pharmacogenetics</kwd><kwd>Myelosuppression</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100010221</institution-id><institution>Higher Education Commision, Pakistan</institution></institution-wrap></funding-source><award-id>91591659</award-id><principal-award-recipient><name name-style="western"><surname>Arshad</surname><given-names>Usman</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">The pyrimidine antimetabolite 5-fluorouracil (5FU) is being used since decades for the treatment of gastrointestinal solid malignancies [<xref ref-type="bibr" rid="CR1">1</xref>]. Dose, but also route and schedule of administration have been identified to influence 5FU pharmacokinetics (PK) and effects [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Considerable variations in PK and toxicity are associated with a given 5FU dosing regimen [<xref ref-type="bibr" rid="CR4">4</xref>]. Investigations have been carried out evaluating patient&#8217;s factors to predict 5FU exposure, where a relationship between body surface area (BSA) and 5FU clearance (CL<sub>5FU</sub>) was reported [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. CL<sub>5FU</sub> was found to be lower in females [<xref ref-type="bibr" rid="CR6">6</xref>] and at older age [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Due to saturable hepatic degradation, 5FU PK is considered to be non-linear in nature [<xref ref-type="bibr" rid="CR8">8</xref>]. Additionally, elimination of the drug was reported to be influenced by hepatic metastases [<xref ref-type="bibr" rid="CR3">3</xref>] and by glomerular filtration rate as measured by creatinine clearance [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par6">Being a prodrug, 5FU requires enzymatic activation. A small fraction of an administered dose is metabolised into cytotoxic nucleotides, while most of the drug is degraded to 5-fluoro-5,6-dihydrouracil (5FUH2) mainly by hepatic dihydropyrimidine dehydrogenase (DPD) [<xref ref-type="bibr" rid="CR9">9</xref>]. Some rare variants of the highly polymorphic DPD gene (<italic toggle="yes">DPYD)</italic> are responsible for complete or partial loss of DPD activity, which is related to increased 5FU toxicity [<xref ref-type="bibr" rid="CR10">10</xref>]. Belonging to the class of antimetabolites, 5FU inhibits thymidylate synthase (TS), ultimately leading to the impairment of DNA synthesis [<xref ref-type="bibr" rid="CR11">11</xref>]. Polymorphisms in the gene encoding TS influence toxicity and response of 5FU-based therapeutic regimens [<xref ref-type="bibr" rid="CR12">12</xref>]. Methylenetetrahydrofolate reductase (MTHFR) is involved in the formation of the reduced folate cofactor, which is required for the inhibition of TS. Genetic polymorphisms in the gene encoding MTHFR are associated with altered enzymatic activity, thereby influencing sensitivity towards 5FU [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par7">5FU is commonly used in combination with other antineoplastic drugs and with radiotherapy. A therapeutic regimen known as FOLFIRINOX including 5FU, folinic acid, oxaliplatin and irinotecan is frequently employed for the treatment of colorectal and pancreatic cancer [<xref ref-type="bibr" rid="CR14">14</xref>]. Another regimen, called de Gramont, includes a combination of 5FU and leucovorin (folinic acid) and has been reported to possess low-toxicity profile, increased response rate and progression-free survival [<xref ref-type="bibr" rid="CR15">15</xref>]. For oesophageal cancer, combination with cisplatin is one of the recommend drug treatments [<xref ref-type="bibr" rid="CR16">16</xref>]. Approximately 10&#8211;30% of 5FU-treated patients experience severe treatment-related toxicity [<xref ref-type="bibr" rid="CR17">17</xref>], where myelosuppression and mucositis have been reported as main dose limiting side effects in 5FU treatment [<xref ref-type="bibr" rid="CR18">18</xref>]. Continuous infusions exhibit lower myelosuppression with greater efficacy and are considered superior over the bolus administrations [<xref ref-type="bibr" rid="CR19">19</xref>]. Furthermore, 5FU has a narrow therapeutic index with severe toxicities tending to occur with AUC values&#8201;&gt;&#8201;25&#160;mg&#160;h/L during continuous venous infusion [<xref ref-type="bibr" rid="CR20">20</xref>]. Therefore, therapeutic drug monitoring is considered valuable to achieve optimal 5FU exposure with minimal serious toxicity [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par8">Semiphysiological myelosuppression models were developed in both animals and human beings to understand time course and extent of leukopenia following administration of cytotoxic antineoplastic drugs, thus facilitating the drug development and therapy [<xref ref-type="bibr" rid="CR22">22</xref>]. Models incorporating white blood cell (WBC) count over time are helpful to predict the time (<italic toggle="yes">T</italic><sub>nadir</sub>) and depth (WBC<sub>nadir</sub>) of lowest total WBC count and the duration of the recovery period to administer the next cycle of a regimen [<xref ref-type="bibr" rid="CR23">23</xref>]. Efforts have been made to predict the time course of myelosuppression by 5FU in rats [<xref ref-type="bibr" rid="CR24">24</xref>]. Population analysis was carried out for the hematological toxicity in breast cancer patients treated with combined 5FU, epirubicin and cyclophosphamide regimen [<xref ref-type="bibr" rid="CR25">25</xref>] but such a study with 5FU monotherapy is lacking.</p><p id="Par9">The objective of the present study was to describe the PK and associated variability of 5FU and its metabolite by developing an empirical model. Subsequently, it was aimed to establish the relationship between 5FU exposure and myelotoxicity through a semi-mechanistic PKPD model. The study was further focused towards the identification and quantitative description of covariates on 5FU PK and myelotoxicity, especially patient demographics and genotypes (<italic toggle="yes">DPYD</italic>, <italic toggle="yes">MTHFR</italic>, <italic toggle="yes">TS</italic>).</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Patients and treatment plan</title><p id="Par10">The study was approved by the Ethics Committee of the Medical Faculty of the University of Cologne, Germany (application number 02-171), and was conducted according to the Declaration of Helsinki and national and international legal stipulations and guidelines in 2002&#8211;2005 [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Sample size was estimated using WinBiAS (version 7.01, epsilon Verlag, Darmstadt, Germany) considering interindividual variability (IIV) in 5FU pharmacokinetics to be at least 30%. To assess the effect of a covariate on 5FU pharmacokinetics, assuming a linear coefficient of correlation <italic toggle="yes">&#961;</italic>&#8201;=&#8201;0.5477 (explaining a fraction of <italic toggle="yes">&#961;</italic><sup>2</sup>&#8201;=&#8201;0.3 of variability) with a power of 90% and <italic toggle="yes">&#945;</italic>&#8201;=&#8201;0.05, <italic toggle="yes">n</italic>&#8201;=&#8201;30 patients were required. To account for possible dropouts, 33 patients with colorectal or oesophageal cancer were planned to be enrolled in the study after the provision of written informed consent. Eligibility criteria included age&#8201;&#8805;&#8201;18&#160;years; Karnofsky performance status&#8201;&#8805;&#8201;70%; life expectancy&#8201;&#8805;&#8201;3&#160;months; adequate haematopoietic, hepatic, and renal function. Exclusion criteria were prior chemotherapy or radiotherapy, and concomitant drugs (not included in the chemotherapeutic regimen) known to interfere with 5FU PK and/or pharmacodynamics. The patients with colorectal cancer received 5FU 650 or 1000&#160;mg/m<sup>2</sup>/day as 24-h continuous venous infusion for 5&#160;days, and radiotherapy. The patients with oesophageal cancer additionally obtained cisplatin 20&#160;mg/m<sup>2</sup>/day for 5&#160;days before, or together with 5FU administration. Any decision on treatment was made according to the clinical situation and was not influenced by the study. WBC count was evaluated once prior to and 1&#8211;3 times per week after 5FU administration, but prior to the second cycle starting on day 28, as the assessment of myelosuppression was aimed to be investigated under the influence of single cycle of treatment. Only the first cycle was monitored in each participant. Covariate data regarding patient demographics and essential laboratory values were collected prior to the treatment.</p></sec><sec id="Sec4"><title>Genotyping</title><p id="Par11">DNA were extracted from peripheral blood using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). For <italic toggle="yes">DPYD</italic> genotyping [<xref ref-type="bibr" rid="CR28">28</xref>], PCR amplification of all 23 coding exons and exon&#8211;intron boundaries of the <italic toggle="yes">DPYD</italic> gene was carried out. PCR products were separated on 1.6% agarose gels, visualized with ethidium bromide and purified using a QIA quick Gel Extraction Kit (Qiagen, Hilden, Germany). Samples were sequenced on an ABI 3100 automated DNA sequencer (Applied Biosystems, Foster City, CA, USA). TS genotyping was carried by PCR amplification [<xref ref-type="bibr" rid="CR29">29</xref>] of the <italic toggle="yes">TS</italic> promoter enhancer region containing the double and triple tandem repeats using the following primers: forward 5&#8242;AAAAGGCGCGCGGAAGGGGTCCT3&#8242;; reverse 5&#8242;TCCGAGCCGGCCACAGGCAT3&#8242;. A total of 32 cycles (94&#160;&#176;C for 40&#160;s, 62&#160;&#176;C for 40&#160;s and 72&#160;&#176;C for 1&#160;min) and extension at 72&#160;&#176;C for 5&#160;min were carried out following hot start at 94&#160;&#176;C for 4&#160;min. The PCR product was analysed in a 3% agarose gel. The triple repeat (3R/3R) had a 144&#160;bp PCR product, the double repeat (2R/2R) a 116&#160;bp product. For <italic toggle="yes">MTHFR</italic> genotyping [<xref ref-type="bibr" rid="CR30">30</xref>], the PCR used forward primer 5&#8242;TGAAGGAGAAGGTGTCTGCGGGA3&#8242; and reverse primer 5&#8242;AGGACGGTGCGCTGAGAGTG3&#8242;. Restriction fragment analysis was carried out using <italic toggle="yes">Hinf</italic> I (Fermentas, St. Leon-Rot, Germany). The C&#8201;&#8594;&#8201;T substitution at nucleotide 667 creates a <italic toggle="yes">Hinf</italic> I digestion site resulting in two fragments (175&#160;bp and 23&#160;bp) of the PCR product.</p></sec><sec id="Sec5"><title>Analysis of 5FU and 5FUH2 plasma concentrations</title><p id="Par12">Analytical-grade reagents were purchased from Merck (Darmstadt, Germany). 5FU (Sigma, St. Louis, MO, USA) was purchased as crystalline form, pure&#8201;&gt;&#8201;95%, 5FUH2 (26.5% pure) was supplied by Syncom (Groningen, The Netherlands), and 5-chlorouracil (5-CU), the internal standard, was obtained from Arcos Organics (Geel, Belgium).</p><p id="Par13">Blood samples (4.5&#160;mL each) were withdrawn during the first cycle using Li<sup>+</sup>-heparinized tubes pre-dose, 36, 48, and 108&#160;h after the start of 5FU infusion, at the end of infusion, and 5, 30, 60 and 90&#160;min thereafter. The samples were immediately placed in an ice water bath and centrifuged at&#8201;+&#8201;4&#160;&#176;C. Plasma was stored at &#8722;&#160;80&#160;&#176;C until analysis. 5FU and 5FUH2 in plasma were quantified by reverse-phase HPLC method with UV detection. Briefly, 0.7&#160;mL of plasma was mixed with 20 &#181;L of 100&#160;&#181;g/mL 5-CU (internal standard) and extracted with 7&#160;mL of isopropanol/ethyl acetate (5:95, v/v). Samples were mixed and centrifuged (3500&#160;rpm, 10&#160;min) to separate the organic phase, which was evaporated to dryness. The samples were reconstituted with 100 &#181;L of 50&#160;mM K<sub>2</sub>HPO<sub>4</sub> (pH 4.0), and 40 &#956;L was injected into the HPLC system. 5FU and 5FUH2 were separated on an Ultrasphere ODS C<sub>18</sub> column (5&#160;&#956;m, 250&#8201;&#215;&#8201;4.6&#160;mm, Beckman Coulter, Brea, CA, USA). Elution was performed under gradient condition as follows: 50&#160;mM K<sub>2</sub>HPO<sub>4</sub> (A) for 17&#160;min, acetonitrile (B) 0&#8211;50% over 1&#160;min and maintained at 50% for 5&#160;min; initial conditions were restored by decreasing B to 0% over 1&#160;min, and the column was equilibrated with 100% A for 5&#160;min. The chromatographic instrument was a Waters 2690 Separations Module (Waters, Milford, MA, USA) with a Waters 996 photodiode array detector. Detection of 5FU, 5FUH2 and 5-CU were carried out at 265, 220 and 270&#160;nm, respectively. Data analysis was performed by the Millennium 2.1 software (Waters, Milford, MA, USA). The LLOQs were 0.005 and 0.01&#160;&#181;g/mL for 5FU and 5FUH2, respectively. The 5FU and 5FUH2 intra-assay coefficients of variation ranged from 0.34 to 7.15% and from 0.53 to 2.76%, respectively, while the inter-assay coefficients of variation for a 5-day validation were 0.1&#8211;3.4% and 2.3&#8211;9.0%, respectively.</p></sec><sec id="Sec6"><title>Data analysis</title><sec id="Sec7"><title>Model development and selection criteria</title><p id="Par14">R (version 3.2.3) was used for data manipulation and exploratory evaluation [<xref ref-type="bibr" rid="CR31">31</xref>]. Population parameter estimates were obtained using first-order conditional estimation with interaction (FOCE-I) algorithm in NONMEM 7.4.2 (ICON, Development Solutions, Elliot City, MD, USA) [<xref ref-type="bibr" rid="CR32">32</xref>]. Model development process was aided by Perl-speaks-NONMEM (PsN) toolkit (Version 4.7.0) [<xref ref-type="bibr" rid="CR33">33</xref>]. IIV in model parameters was estimated assuming a log-normal distribution. Additive, proportional and combined error models were implemented to estimate residual unexplained variabilities (RUV) for 5FU and 5FUH2. Model selection/rejection was guided by a decrease in objective function value (OFV) which was assumed to be chi-squared distributed (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, corresponding to a &#916;OFV&#8201;&#8805;&#8201;3.84 given a change by one degree of freedom), diagnostic plots, scientific plausibility and precision of parameter estimates. Precision of population parameter estimates was assessed with the help of a bootstrap procedure using 1000 sample replicates.</p></sec><sec id="Sec8"><title>Pharmacokinetic analysis</title><p id="Par15">An empirical compartmental model for 5FU was first developed and then expanded to a combined model incorporating 5FUH2 data. The drug was presumed to be eliminated from the central compartment where elimination was tested to follow either a linear behaviour or nonlinear Michaelis&#8211;Menten kinetics. The fraction of 5FU converted to 5FUH2 was fixed a priori to 0.85, according to the literature [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. PK parameters were estimated based on the absolute dose administered.</p></sec><sec id="Sec9"><title>Pharmacodynamic analysis</title><p id="Par16">The PD model was developed according to Friberg et al. [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR34">34</xref>] using simultaneous approach. The model was driven by 5FU plasma concentrations from the PK model and comprised a compartment of proliferating leukocytes (rate constant describing the proliferation of cells: <italic toggle="yes">k</italic><sub>prol</sub>), transit compartments representing leukocytes undergoing maturation (rate constant describing the transfer between transit compartments: <italic toggle="yes">k</italic><sub>tr</sub>) and a compartment of circulating leukocytes (rate constant describing the rate of exit from the circulating compartment: <italic toggle="yes">k</italic><sub>circ</sub>). Parameters were the baseline circulating leukocyte count (Circ<sub>0</sub>) representing the number of cells prior to 5FU administration, mean transit time (MTT&#8201;=&#8201;[<italic toggle="yes">n</italic>&#8201;+&#8201;1]/<italic toggle="yes">k</italic><sub>tr,</sub> where <italic toggle="yes">n</italic> denotes the number of transit compartments) and a parameter <italic toggle="yes">&#947;</italic> describing a negative feedback of circulating cells on the rate of self&#8208;renewal of the proliferative cells (feedback&#8201;=&#8201;[Circ<sub>0</sub>/Circ]<sup><italic toggle="yes">&#947;</italic></sup>). The number of parameters to be estimated were minimized by assuming <italic toggle="yes">k</italic><sub>prol</sub>&#8201;=&#8201;<italic toggle="yes">k</italic><sub>tr</sub>&#8201;=&#8201;<italic toggle="yes">k</italic><sub>circ</sub>. 5FU plasma concentrations were assumed to inhibit the proliferation of leukocytes.</p><p id="Par17">The drug effect (<italic toggle="yes">E</italic><sub>drug</sub>) on proliferating cells was assumed to be driven by individual predicted 5FU plasma concentrations (<italic toggle="yes">C</italic><sub>p</sub>) and was incorporated into the model as <italic toggle="yes">k</italic><sub>prol</sub>&#8201;&#215;&#8201;(1&#160;&#8722;&#160;<italic toggle="yes">E</italic><sub>drug</sub>). <italic toggle="yes">E</italic><sub>drug</sub> was either formulated as a linear model (<italic toggle="yes">E</italic><sub>drug</sub>&#8201;=&#8201;slope&#8201;&#215;&#8201;<italic toggle="yes">C</italic><sub>p</sub>) or a nonlinear model (<italic toggle="yes">E</italic><sub>drug</sub>&#8201;=&#8201;<italic toggle="yes">E</italic><sub>max</sub>&#8201;&#215;&#8201;<italic toggle="yes">C</italic><sub>p</sub>/(EC<sub>50</sub>&#8201;+&#8201;<italic toggle="yes">C</italic><sub>p</sub>)).</p></sec><sec id="Sec10"><title>Covariate analysis</title><p id="Par18">Covariates tested in the PK analysis included demographics (age, weight, height, sex, body mass index, lean body weight, BSA); predose plasma concentrations of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and &#947;-glutamyltransferase (&#947;-GT), and albumin; and <italic toggle="yes">DPYD, TS</italic> and <italic toggle="yes">MTHFR</italic> genotypes. The effect of co-medication with cisplatin was tested on the slope of the linear effect model. Scientific plausibility was the primary basis for covariate pre-selection, while graphical evaluation (residuals and individual PK estimates versus covariates) was performed to assist the inclusion decision. A comparative analysis was carried out to assess any possible superiority of other indices representing body mass over the BSA such as BMI, LBW and allometric scaling with body weight.</p></sec><sec id="Sec11"><title>Simulation design</title><p id="Par19">The effect of concomitant cisplatin administration on leukocyte suppression was evaluated. WBC counts over time were simulated for virtual subjects receiving a 5-day continuous infusion with and without cisplatin co-medication. WBC<sub>nadir</sub> and <italic toggle="yes">T</italic><sub>nadir</sub> for the respective regimens were determined to assess the degree of myelosuppression.</p><p id="Par20">Another simulation scenario aimed towards the comparative assessment of the time course of myelosuppression theoretically produced by the 5FU component contained in a single cycle of the two standard dosage regimens used in current clinical practice; to this end, the effects of the other components of the regimens were ignored. The standard FOLFIRINOX regimen combines oxaliplatin (85&#160;mg/m<sup>2</sup> over 2&#160;h) with folinic acid (200&#160;mg/m<sup>2</sup>) followed by irinotecan (180&#160;mg/m<sup>2</sup> over 90&#160;min) and 5FU (400&#160;mg/m<sup>2</sup> bolus) followed by 2400&#160;mg/m<sup>2</sup> 5FU over 46&#160;h, all on day 1 and repeated every 2&#160;weeks [<xref ref-type="bibr" rid="CR14">14</xref>]. The de Gramont regimen is described as follows: high-dose folinic acid (200&#160;mg/m<sup>2</sup>) followed by 5FU i.v. bolus (300&#160;mg/m<sup>2</sup>) and continuous infusion (300&#160;mg/m<sup>2</sup>) on days 1, 2, 14 and 15, repeated every 4&#160;weeks. In the absence of toxicity, 5-FU is increased to 400&#160;mg/m<sup>2</sup> i.v. bolus and continuous infusion at course 2 and to 500&#160;mg/m<sup>2</sup> at course 3 and from course 4 maintained at 500&#160;mg/m<sup>2</sup> [<xref ref-type="bibr" rid="CR15">15</xref>]. Simulated WBC<sub>nadir</sub> and <italic toggle="yes">T</italic><sub>nadir</sub> were observed for the treatment with FOLFIRINOX (400&#160;mg/m<sup>2</sup> bolus 5FU followed by 2400&#160;mg/m<sup>2</sup> 5FU over 46&#160;h) and de Gramont (5FU 300&#160;mg/m<sup>2</sup> i.v. bolus followed by 300&#160;mg/m<sup>2</sup> continuous infusion over 24&#160;h) regimens.</p></sec></sec></sec><sec id="Sec12"><title>Results</title><sec id="Sec13"><title>Patient characteristics</title><p id="Par21">Thirty-three patients were included in the study; of these, three patients dropped out prior to the first administration of 5-FU. The remaining 30 patients who all completed the study comprised 5 women and 25 men with an age ranging between 37 and 73&#160;years. 16 patients with colorectal cancer were administered 5FU only, while 14 with oesophageal cancer were treated with the combination of 5FU with cisplatin. Patient demographics, primary tumor location, pre-treatment values of haematology and clinical chemistry parameters are summarized in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Patient characteristics (<italic toggle="yes">n</italic>&#8201;=&#8201;30)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Characteristics</th><th align="left" colspan="1" rowspan="1">Value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Sex (<italic toggle="yes">n</italic> male/ <italic toggle="yes">n</italic> female)</td><td align="left" colspan="1" rowspan="1">25/5</td></tr><tr><td align="left" colspan="1" rowspan="1">Median age, years (range)</td><td align="left" colspan="1" rowspan="1">59.5 (37&#8211;73)</td></tr><tr><td align="left" colspan="1" rowspan="1">Median Karnofsky performance status (range)</td><td align="left" colspan="1" rowspan="1">100% (100&#8211;100)</td></tr><tr><td align="left" colspan="1" rowspan="1">Tumour primary site (<italic toggle="yes">n</italic>)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Oesophagus</td><td align="left" colspan="1" rowspan="1">14</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Rectal</td><td align="left" colspan="1" rowspan="1">2</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Colorectal</td><td align="left" colspan="1" rowspan="1">13</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Anus</td><td align="left" colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">Median body height, m (range)</td><td align="left" colspan="1" rowspan="1">1.75 (1.61&#8211;1.86)</td></tr><tr><td align="left" colspan="1" rowspan="1">Median body weight, kg (range)</td><td align="left" colspan="1" rowspan="1">76 (46&#8211;111)</td></tr><tr><td align="left" colspan="1" rowspan="1">Median BMI, kg/m<sup>2</sup> (range)</td><td align="left" colspan="1" rowspan="1">24.2 (16.9&#8211;33.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Median BSA, m<sup>2</sup> (range)</td><td align="left" colspan="1" rowspan="1">1.95 (1.48&#8211;2.33)</td></tr><tr><td align="left" colspan="1" rowspan="1">Median baseline laboratory values (range)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Haemoglobin (g/dL)</td><td align="left" colspan="1" rowspan="1">13.7 (10.1&#8211;16.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Platelet count (&#215;&#8201;10<sup>3</sup>/&#181;L)</td><td align="left" colspan="1" rowspan="1">277 (48&#8211;426)</td></tr><tr><td align="left" colspan="1" rowspan="1">Erythrocyte count (&#215;&#8201;10<sup>6</sup>/&#181;L)</td><td align="left" colspan="1" rowspan="1">4.6 (3.8&#8211;5.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Leukocyte count (&#215;&#8201;10<sup>9</sup>/L)</td><td align="left" colspan="1" rowspan="1">6.90 (4.68&#8211;11.28)</td></tr><tr><td align="left" colspan="1" rowspan="1">Plasma albumin (g/dL)</td><td align="left" colspan="1" rowspan="1">42 (35&#8211;47)</td></tr><tr><td align="left" colspan="1" rowspan="1">Plasma ASAT (U/L)</td><td align="left" colspan="1" rowspan="1">18 (9&#8211;50)</td></tr><tr><td align="left" colspan="1" rowspan="1">Plasma ALAT (U/L)</td><td align="left" colspan="1" rowspan="1">15 (8&#8211;90)</td></tr><tr><td align="left" colspan="1" rowspan="1">Plasma &#947;-GT (U/L)</td><td align="left" colspan="1" rowspan="1">24 (13&#8211;81)</td></tr><tr><td align="left" colspan="1" rowspan="1">Plasma total bilirubin (mg/dL)</td><td align="left" colspan="1" rowspan="1">0.45 (0.4&#8211;0.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Plasma creatinine (mg/dL)</td><td align="left" colspan="1" rowspan="1">0.85 (0.44&#8211;1.06)</td></tr><tr><td align="left" colspan="1" rowspan="1">Co-medication with cisplatin (<italic toggle="yes">n</italic>)</td><td align="left" colspan="1" rowspan="1">14</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">BSA</italic> body surface area, <italic toggle="yes">BMI</italic> body mass index, <italic toggle="yes">ASAT</italic> aspartate aminotransferase, <italic toggle="yes">ALAT</italic> alanine aminotransferase, <italic toggle="yes">&#947;-GT</italic> gamma-glutamyl transferase</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec14"><title>Genotypes</title><p id="Par22">Analysis of the <italic toggle="yes">DPYD</italic> gene revealed the presence of 6 polymorphisms in 22 of 30 patients. Eight patients had multiple mutations in the coding region of the <italic toggle="yes">DPYD</italic> gene (Table <xref rid="Tab2" ref-type="table">2</xref>). None of the known rare (&lt;&#8201;2%) mutations causing extremely reduced or absent DPD activity, such as exon 14 (<italic toggle="yes">DPYD*2A</italic>) G&gt;A skipping mutation [<xref ref-type="bibr" rid="CR35">35</xref>], was found in the study population. The six <italic toggle="yes">DPYD</italic> polymorphisms detected in our study were considered to result in either normal (i.e. 1236G&gt;A [<xref ref-type="bibr" rid="CR36">36</xref>]) or partially reduced enzyme activity [<xref ref-type="bibr" rid="CR37">37</xref>].<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Allele frequencies of polymorphisms in the <italic toggle="yes">DPYD</italic> gene found in patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" rowspan="1">Polymorphisms in the <italic toggle="yes">DPYD</italic> gene</th><th align="left" rowspan="2" colspan="1">Effect (nucleotide change)</th><th align="left" rowspan="2" colspan="1">Wild type (<italic toggle="yes">n</italic>)</th><th align="left" rowspan="2" colspan="1">Heterozygous mutant (<italic toggle="yes">n</italic>)</th><th align="left" rowspan="2" colspan="1">Homozygous mutant (<italic toggle="yes">n</italic>)</th><th align="left" rowspan="2" colspan="1">Allelic frequency (%)</th></tr><tr><th align="left" colspan="1" rowspan="1"><sup>a</sup><italic toggle="yes">DPYD</italic> nomenclature</th><th align="left" colspan="1" rowspan="1">Exon</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">DPYD</italic><italic toggle="yes">*</italic><italic toggle="yes">9A</italic></td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Cys29Arg (85T&gt;C)</td><td char="." align="char" colspan="1" rowspan="1">20</td><td char="." align="char" colspan="1" rowspan="1">8</td><td char="." align="char" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">12/60 (20%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Met166Val (496A&gt;G)</td><td char="." align="char" colspan="1" rowspan="1">22</td><td char="." align="char" colspan="1" rowspan="1">8</td><td char="." align="char" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">8/60 (13.33%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">Glu412Glu (1236G&gt;A)</td><td char="." align="char" colspan="1" rowspan="1">29</td><td char="." align="char" colspan="1" rowspan="1">1</td><td char="." align="char" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">1/60 (1.67%)</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">DPYD</italic><italic toggle="yes">*</italic><italic toggle="yes">4</italic></td><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">Ser534Asn (1601G&gt;A)</td><td char="." align="char" colspan="1" rowspan="1">29</td><td char="." align="char" colspan="1" rowspan="1">1</td><td char="." align="char" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">1/60 (1.67%)</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">DPYD</italic><italic toggle="yes">*</italic><italic toggle="yes">5</italic></td><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">Ile543Val (1627A&gt;G)</td><td char="." align="char" colspan="1" rowspan="1">19</td><td char="." align="char" colspan="1" rowspan="1">9</td><td char="." align="char" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">13/60 (21.67%)</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">DPYD</italic><italic toggle="yes">*</italic><italic toggle="yes">6</italic></td><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">Val732Ile (2194G&gt;A)</td><td char="." align="char" colspan="1" rowspan="1">28</td><td char="." align="char" colspan="1" rowspan="1">2</td><td char="." align="char" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">2/60 (3.33%)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">DPYD</italic> dihydropyrimidine dehydrogenase gene</p><p><sup>a</sup>Source of nomenclature: Mcleod et al<italic toggle="yes">.</italic> [<xref ref-type="bibr" rid="CR44">44</xref>]</p></table-wrap-foot></table-wrap></p><p id="Par23">With regard to the <italic toggle="yes">TS</italic> genotype, 5 (16.7%) patients were homozygous for the triple repeat (3R/3R), 19 (63.3%) were heterozygous (2R/3R), and 6 (20%) were homozygous (2R/2R) for the double repeat variant within the <italic toggle="yes">TS</italic> promoter region. As for C677T <italic toggle="yes">MTHFR</italic> genotype, 13 of 30 patients (43.3%) were CC (wild type), 12 (40%)&#8212;CT (heterozygous mutant), and 5 (16.7%)&#8212;TT (homozygous mutant).</p></sec><sec id="Sec15"><title>Pharmacokinetic model</title><p id="Par24">199 and 251 quantifiable plasma concentrations of 5FU and 5FUH2, respectively, were part of the pharmacokinetic model development. Figure&#160;<xref rid="Fig1" ref-type="fig">1</xref> provides a schematic representation of the PKPD model. A two-compartment model with linear elimination (&#8710;OFV of 210 compared to one-compartment model) best described the 5FU concentration&#8211;time data, and a one-compartment model was appropriate for the 5FUH2 data. IIV in the combined model was included for CL<sub>5FU</sub>, CL<sub>5FUH2</sub>, <italic toggle="yes">V</italic><sub>C,5FU</sub> and <italic toggle="yes">V</italic><sub>C,5FUH2</sub>. IIV on <italic toggle="yes">V</italic><sub>P,5FU</sub> was removed because of a high shrinkage value, while IIV on intercompartmental clearance (<italic toggle="yes">Q</italic>) was negligible and hence removed from the final model. A proportional error model was appropriate to model RUV for both 5FU and 5FUH2. Visual predictive checks (VPCs) indicated an adequate prediction of the 5FU and 5FUH2 concentrations by the model (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Population pharmacokinetic parameter estimates are presented in Table <xref rid="Tab3" ref-type="table">3</xref>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Schematic representation of PKPD model. Compartments with white background reflect the PK model describing 5FU and 5FUH2 plasma concentrations, while those with grey background reflect the PD model describing total WBC count over time. <italic toggle="yes">k</italic><sub><italic toggle="yes">prol</italic></sub> first order rate constant of proliferation, <italic toggle="yes">k</italic><sub><italic toggle="yes">tr</italic></sub> first-order rate constant of transit, <italic toggle="yes">k</italic><sub><italic toggle="yes">circ</italic></sub> first-order rate constant of elimination of circulating cells, <italic toggle="yes">Circ</italic><sub><italic toggle="yes">0</italic></sub> baseline leucocyte count, <italic toggle="yes">&#947;</italic> feedback parameter, <italic toggle="yes">C</italic><sub><italic toggle="yes">p</italic></sub> 5FU plasma concentration, <italic toggle="yes">V</italic><sub><italic toggle="yes">C,5FU</italic></sub> 5FU central volume of distribution, <italic toggle="yes">V</italic><sub><italic toggle="yes">P,5FU</italic></sub> 5FU peripheral volume of distribution, <italic toggle="yes">CL</italic><sub><italic toggle="yes">5FU</italic></sub> 5FU total clearance, <italic toggle="yes">Q</italic> intercompartmental clearance, <italic toggle="yes">F</italic><sub><italic toggle="yes">m</italic></sub> fraction of 5FU converted to 5FUH2, <italic toggle="yes">V</italic><sub><italic toggle="yes">C,5FUH2</italic></sub> 5FUH2 central volume of distribution, <italic toggle="yes">CL</italic><sub><italic toggle="yes">5FUH2</italic></sub> 5FUH2 clearance, drug effect: <italic toggle="yes">E</italic><sub>drug</sub>&#8201;=&#8201;slope&#183;<italic toggle="yes">C</italic><sub>p</sub></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="280_2019_4028_Fig1_HTML.jpg"/></fig><fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Visual predictive checks for 5FU (<bold>a</bold>) and 5FUH2 (<bold>b</bold>) plasma concentration data and total WBC count (<bold>c</bold>) over time. Continuous and dashed lines represent median, 2.5th and 97.5th percentiles of the observed data. Shaded areas are the 95% confidence interval for median, 2.5th and 97.5th percentiles of the simulated data. 5FU and 5FUH2 plasma concentrations are presented on a log scale</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="280_2019_4028_Fig2_HTML.jpg"/></fig><table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Population pharmacokinetic and pharmacodynamic parameter estimates</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Parameter</th><th align="left" colspan="2" rowspan="1">NONMEM estimates</th><th align="left" colspan="1" rowspan="1">NONMEM RSE (%)</th><th align="left" colspan="2" rowspan="1">Bootstrap estimates</th><th align="left" colspan="1" rowspan="1">Bootstrap RSE (%)</th><th align="left" colspan="1" rowspan="1">95% CI</th></tr></thead><tbody><tr><td align="left" colspan="8" rowspan="1">5FU</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;CL<sub>5FU</sub> (L/h)</td><td align="left" colspan="1" rowspan="1">256</td><td align="left" colspan="2" rowspan="1">5.47</td><td align="left" colspan="1" rowspan="1">249</td><td align="left" colspan="2" rowspan="1">6.36</td><td align="left" colspan="1" rowspan="1">224&#8211;276</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<italic toggle="yes">V</italic><sub>C,5FU</sub> (L)</td><td align="left" colspan="1" rowspan="1">5.85</td><td align="left" colspan="2" rowspan="1">39.3</td><td align="left" colspan="1" rowspan="1">5.56</td><td align="left" colspan="2" rowspan="1">42.0</td><td align="left" colspan="1" rowspan="1">2.41&#8211;9.87</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<italic toggle="yes">V</italic><sub>P,5FU</sub> (L)</td><td align="left" colspan="1" rowspan="1">24.0</td><td align="left" colspan="2" rowspan="1">22.9</td><td align="left" colspan="1" rowspan="1">28.5</td><td align="left" colspan="2" rowspan="1">81.5</td><td align="left" colspan="1" rowspan="1">13.3&#8211;59.3</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<italic toggle="yes">Q</italic> (L/h)</td><td align="left" colspan="1" rowspan="1">17.3</td><td align="left" colspan="2" rowspan="1">30.7</td><td align="left" colspan="1" rowspan="1">14.8</td><td align="left" colspan="2" rowspan="1">29.8</td><td align="left" colspan="1" rowspan="1">9.66&#8211;23.4</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;BSA effect (m<sup>&#8722;2</sup>)<sup>a</sup></td><td align="left" colspan="1" rowspan="1">0.71</td><td align="left" colspan="2" rowspan="1">23.5</td><td align="left" colspan="1" rowspan="1">0.77</td><td align="left" colspan="2" rowspan="1">28.0</td><td align="left" colspan="1" rowspan="1">0.44&#8211;1.14</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;AUC<sub>24,5FU</sub> (mg h/L)<sup>b</sup></td><td align="left" colspan="1" rowspan="1">6.72</td><td align="left" colspan="2" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">6.72</td><td align="left" colspan="2" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">4.76&#8211;8.74</td></tr><tr><td align="left" colspan="8" rowspan="1">5FUH2</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<italic toggle="yes">F</italic><sub>m</sub> (%)</td><td align="left" colspan="1" rowspan="1">85</td><td align="left" colspan="2" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">85</td><td align="left" colspan="2" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Fixed</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;CL<sub>5FUH2</sub> (L/h)</td><td align="left" colspan="1" rowspan="1">124</td><td align="left" colspan="2" rowspan="1">6.61</td><td align="left" colspan="1" rowspan="1">121</td><td align="left" colspan="2" rowspan="1">7.11</td><td align="left" colspan="1" rowspan="1">108&#8211;136</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<italic toggle="yes">V</italic><sub>C,5FUH2</sub> (L)</td><td align="left" colspan="1" rowspan="1">100</td><td align="left" colspan="2" rowspan="1">13.0</td><td align="left" colspan="1" rowspan="1">96.7</td><td align="left" colspan="2" rowspan="1">14.37</td><td align="left" colspan="1" rowspan="1">74.8&#8211;119</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;AUC<sub>24,5FUH2</sub> (mg h/L)<sup>b</sup></td><td align="left" colspan="1" rowspan="1">12.2</td><td align="left" colspan="2" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">12.2</td><td align="left" colspan="2" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">7.12&#8212;19.2</td></tr><tr><td align="left" colspan="8" rowspan="1">Total WBC count</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;CIRC<sub>0</sub> (&#215;&#8201;10<sup>9</sup>/L)</td><td align="left" colspan="1" rowspan="1">7.16</td><td align="left" colspan="2" rowspan="1">5.23</td><td align="left" colspan="1" rowspan="1">6.86</td><td align="left" colspan="2" rowspan="1">4.50</td><td align="left" colspan="1" rowspan="1">6.38&#8211;7.37</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;MTT (h)</td><td align="left" colspan="1" rowspan="1">261</td><td align="left" colspan="2" rowspan="1">6.70</td><td align="left" colspan="1" rowspan="1">281</td><td align="left" colspan="2" rowspan="1">13.1</td><td align="left" colspan="1" rowspan="1">224&#8211;344</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Slope<sub>comb</sub> (L/mg)</td><td align="left" colspan="1" rowspan="1">2.10</td><td align="left" colspan="2" rowspan="1">18.9</td><td align="left" colspan="1" rowspan="1">2.82</td><td align="left" colspan="2" rowspan="1">27.2</td><td align="left" colspan="1" rowspan="1">1.53&#8211;3.77</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Slope<sub>mono</sub> (L/mg)</td><td align="left" colspan="1" rowspan="1">1.31</td><td align="left" colspan="2" rowspan="1">44.2</td><td align="left" colspan="1" rowspan="1">1.17</td><td align="left" colspan="2" rowspan="1">25.0</td><td align="left" colspan="1" rowspan="1">0.78&#8211;1.72</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<italic toggle="yes">&#947;</italic></td><td align="left" colspan="1" rowspan="1">0.17</td><td align="left" colspan="2" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.17</td><td align="left" colspan="2" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Fixed</td></tr><tr><td align="left" colspan="8" rowspan="1">IIV (%CV)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;CL<sub>5FU</sub></td><td align="left" colspan="1" rowspan="1">24.9</td><td align="left" colspan="2" rowspan="1">17.2</td><td align="left" colspan="1" rowspan="1">23.0</td><td align="left" colspan="2" rowspan="1">43.1</td><td align="left" colspan="1" rowspan="1">12.3&#8211;30.1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<italic toggle="yes">V</italic><sub>C,5FU</sub></td><td align="left" colspan="1" rowspan="1">130</td><td align="left" colspan="2" rowspan="1">45.4</td><td align="left" colspan="1" rowspan="1">145</td><td align="left" colspan="2" rowspan="1">57.0</td><td align="left" colspan="1" rowspan="1">75.3&#8211;204</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;CL<sub>5FUH2</sub></td><td align="left" colspan="1" rowspan="1">30.5</td><td align="left" colspan="2" rowspan="1">27.1</td><td align="left" colspan="1" rowspan="1">28.9</td><td align="left" colspan="2" rowspan="1">28.0</td><td align="left" colspan="1" rowspan="1">21.8&#8211;35.1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<italic toggle="yes">V</italic><sub>C,5FUH2</sub></td><td align="left" colspan="1" rowspan="1">58.9</td><td align="left" colspan="2" rowspan="1">62.7</td><td align="left" colspan="1" rowspan="1">59.6</td><td align="left" colspan="2" rowspan="1">76.8</td><td align="left" colspan="1" rowspan="1">30.7&#8211;96.3</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;CIRC<sub>0</sub></td><td align="left" colspan="1" rowspan="1">16.8</td><td align="left" colspan="2" rowspan="1">69.6</td><td align="left" colspan="1" rowspan="1">16.4</td><td align="left" colspan="2" rowspan="1">52.0</td><td align="left" colspan="1" rowspan="1">8.29&#8211;22.8</td></tr><tr><td align="left" colspan="8" rowspan="1">RUV (<italic toggle="yes">&#963;</italic>2)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Proportional error 5FU</td><td align="left" colspan="1" rowspan="1">0.36</td><td align="left" colspan="2" rowspan="1">10.2</td><td align="left" colspan="1" rowspan="1">0.32</td><td align="left" colspan="2" rowspan="1">9.37</td><td align="left" colspan="1" rowspan="1">0.23&#8211;0.44</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Proportional error 5FUH2</td><td align="left" colspan="1" rowspan="1">0.14</td><td align="left" colspan="2" rowspan="1">8.06</td><td align="left" colspan="1" rowspan="1">0.14</td><td align="left" colspan="2" rowspan="1">9.61</td><td align="left" colspan="1" rowspan="1">0.10&#8211;0.18</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Proportional error total WBC count</td><td align="left" colspan="1" rowspan="1">0.08</td><td align="left" colspan="2" rowspan="1">8.70</td><td align="left" colspan="1" rowspan="1">0.08</td><td align="left" colspan="2" rowspan="1">8.97</td><td align="left" colspan="1" rowspan="1">0.06&#8211;0.11</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">RSE</italic> relative standard error, <italic toggle="yes">CI</italic> confidence interval, <italic toggle="yes">CL</italic><sub><italic toggle="yes">5FU</italic></sub> total clearance of 5FU, <italic toggle="yes">V</italic><sub><italic toggle="yes">C,5FU</italic></sub> 5FU central volume of distribution, <italic toggle="yes">V</italic><sub><italic toggle="yes">P,5FU</italic></sub> 5FU peripheral volume of distribution, <italic toggle="yes">Q</italic> intercompartmental clearance, <italic toggle="yes">BSA</italic> body surface area, <italic toggle="yes">F</italic><sub><italic toggle="yes">m</italic></sub> fraction of 5FU converted to 5FUH2, <italic toggle="yes">CL</italic><sub><italic toggle="yes">5FUH2</italic></sub> clearance of 5FUH2, <italic toggle="yes">CIRC</italic><sub><italic toggle="yes">0</italic></sub> baseline leukocyte count, <italic toggle="yes">MTT</italic> mean transit time, <italic toggle="yes">Slope</italic><sub><italic toggle="yes">comb</italic></sub> slope parameter for combination therapy with cisplatin, <italic toggle="yes">Slope</italic><sub><italic toggle="yes">mono</italic></sub> slope parameter for 5FU monotherapy, The &#8220;Slope&#8221; parameter represents the relationship between effect and drug concentration into bone marrow (<italic toggle="yes">E</italic><sub>drug</sub>&#8201;=&#8201;slope&#8201;&#215;&#8201;<italic toggle="yes">C</italic><sub>p</sub>), <italic toggle="yes">C</italic><sub>p</sub> plasma concentration, <italic toggle="yes">IIV</italic> interindividual variability, <italic toggle="yes">RUV</italic> residual unexplained variability, <italic toggle="yes">CV</italic> coefficient of variation</p><p><sup>a</sup>Fractional change in CL per m<sup>2</sup> difference from median BSA value</p><p><sup>b</sup>Calculated by obtaining time integral of drug concentrations using an additional compartment in NONMEM</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec16"><title>Pharmacodynamic model</title><p id="Par25">In total, 135 observations for total WBC count were available for 29 patients. None of the patients received a WBC count-modifying drug (e.g. filgrastim). The semi-mechanistic model with three transit compartments adequately described the time course of myelosuppression (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). A linear model was preferred over an <italic toggle="yes">E</italic><sub>max</sub> model, as the <italic toggle="yes">E</italic><sub>max</sub> model did not provide any additional goodness-of-fit to describe the PK/PD relationship. The estimated parameter <italic toggle="yes">&#947;</italic> for the feedback mechanism was inconsistent across different runs and was, therefore, fixed to a value of 0.17 according to the available literature [<xref ref-type="bibr" rid="CR22">22</xref>]. Fixing the parameter estimate for <italic toggle="yes">&#947;</italic> did not have a significant impact on the model fit (&#8710;OFV&#8201;=&#8201;3.68). IIV on MTT and slope were not kept in the final model as they displayed high shrinkage and provided no further improvement with &#8710;OFV values of 1.32 and 0.09, respectively. A proportional error model was found adequate to model RUV. Pharmacodynamic parameter estimates are presented in Table <xref rid="Tab3" ref-type="table">3</xref>.</p></sec><sec id="Sec17"><title>Covariate relationships</title><p id="Par26">Estimated IIV in CL<sub>5FU</sub> in the covariate-free model was 32.8% (CV), whereas a 9% reduction in IIV resulted from the inclusion of BSA as covariate. Scaling with BSA (&#8710;OFV&#8201;=&#8201;10.1) was found superior to that with LBW (&#8710;OFV&#8201;=&#8201;6.4), BMI (&#8710;OFV&#8201;=&#8201;4.3) and body weight (&#8710;OFV&#8201;=&#8201;5.0). CL<sub>5FU</sub> point estimates were 263 L/h [231&#8211;295] and 175 L/h [87&#8211;263] in patients with wild-type <italic toggle="yes">DPYD</italic> genotype and homozygous mutations, respectively. Precision of these estimates was poor, and the effect of <italic toggle="yes">DPYD</italic> was not statistically significant, probably due to small number of mutations in the <italic toggle="yes">DPYD</italic> gene found in the studied population. IIV of CL<sub>5FU</sub> was correlated to <italic toggle="yes">MTHFR</italic> genotype with a &#8710;OFV of 8.98, but the covariate effect was not included in the model because of limitations with regard to mechanistic plausibility. Scaling CL<sub>5FUH2</sub> with individual BSA reduced OFV by 6.76 points with a marginal reduction in IIV (~&#8201;2.1%). The estimate for BSA effect on CL<sub>5FUH2</sub> (0.73&#160;m<sup>&#8722;2</sup>) was close to that on CL<sub>5FU</sub> (0.79&#160;m<sup>&#8722;2</sup>); therefore, the BSA effect was included as a single parameter in the final model assuming a similarity in disposition kinetics between 5FU and 5FUH2. Using single parameter instead of two separate parameters provided no significant change in model fit (&#8710;OFV&#8201;=&#8201;0.35). Inclusion of cisplatin co-medication as a covariate upon slope parameter provided an improvement in model fit by reduction of 18.6 OFV points. Thus, the covariate relationship part of the PKPD model included effects of BSA on CL<sub>5FU</sub> and CL<sub>5FUH2</sub>, and of cisplatin comedication on slope.</p><p id="Par27">Bootstrap analysis using the final PKPD model including the covariate relationships resulted in 681 runs with successful minimization, 318 runs with rounding errors, whereas only a single run failed during the execution. Parameter estimates obtained from bootstrapping were very close to NONMEM estimates (Table <xref rid="Tab3" ref-type="table">3</xref>).</p></sec><sec id="Sec18"><title>Simulated total WBC count over time</title><p id="Par28">Differences in simulated WBC count over time for 5FU monotherapy (5FU<sub>mono</sub>) and combination therapy (5FU<sub>comb</sub>) are presented in Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref> (left panel). A higher degree of myelosuppression was observed for the typical individual receiving 5FU<sub>comb</sub> in comparison to the individual receiving 5FU<sub>mono</sub>. Simulated temporal changes in total WBC count (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>, right panel) showed a higher degree of myelosuppression for virtual subjects administered with the higher 5FU exposure in FOLFIRINOX regimen in comparison to de Gramont regimen.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Left panel; simulated total WBC count over time. Continuous line represents individuals receiving 5FU monotherapy. Dashed line represents individuals receiving combination therapy with 5FU and cisplatin. Numbers represent corresponding WBC<sub>nadir</sub> values. Right panel: simulated total WBC over time for effects attributable to a 5FU dose as used in the FOLFIRINOX (400&#160;mg/m<sup>2</sup> bolus 5FU followed by 2400&#160;mg/m<sup>2</sup> over 46&#160;h) versus the de Gramont regimens (300&#160;mg/m<sup>2</sup> i.v. bolus followed by 300&#160;mg/m<sup>2</sup> continuous infusion over 24&#160;h): Continuous lines represent an individual receiving 5FU according to de Gramont regimen, while dashed lines represent an individual receiving the dose according to FOLFIRINOX regimen. Effects apply for a single treatment course, and those of the other components of the respective regimens are ignored in this figure. Numbers represent corresponding WBC<sub>nadir</sub> values</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="280_2019_4028_Fig3_HTML.jpg"/></fig></p></sec></sec><sec id="Sec19"><title>Discussion</title><p id="Par29">A semi-physiological PK/PD model of 5FU during continuous venous infusion was developed. Covariate effects including genetic variants of the main enzymes involved in 5FU PK and myelosuppression were tested. BSA was identified as a factor significantly influencing 5FU pharmacokinetics. Cisplatin co-administration was found to aggravate myelotoxicity. The current investigations are of particular value because they establish a link between 5FU PK and myelosuppression in the same patients, where we were also able to characterize the PD interaction between 5FU and cisplatin.</p><p id="Par30">Approaches adapted to describe pharmacokinetics of 5FU have been nicely summarized by Deyme et al. [<xref ref-type="bibr" rid="CR14">14</xref>]. In most of the cases, a two-compartment model was found adequate to describe 5FU PK [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR37">37</xref>&#8211;<xref ref-type="bibr" rid="CR39">39</xref>], while some studies presented a one-compartment model [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Most of these studies demonstrated a linear elimination [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR41">41</xref>], whereas a nonlinear elimination was also observed occasionally [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Both linear and nonlinear elimination kinetics were reported in one case [<xref ref-type="bibr" rid="CR39">39</xref>]. In the current evaluation, a two-compartment model with linear elimination was the best to describe 5-FU PK. CL<sub>5FU</sub> of 249 L/h was comparable to the estimates obtained in similarly designed studies. Non-compartmental analysis with a 5-day continuous infusion estimated the CL<sub>5FU</sub> to be 257 L/h [<xref ref-type="bibr" rid="CR42">42</xref>], while an estimate of 270 L/h was reported for a 3-day continuous infusion [<xref ref-type="bibr" rid="CR43">43</xref>]. Population pharmacokinetic analysis performed by Etienne et al. presented an estimate of 235 L/h, where the data were described by a one-compartment model with first-order elimination [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par31">BSA and C677T <italic toggle="yes">MTHFR</italic> genotype were significant covariates in our model. Despite the long-term use of BSA for 5FU dose individualization in clinical practice, existing studies provided conflicting results regarding suitability of BSA for the prediction of 5FU exposure. Some studies did not report any significant relationship between BSA and 5FU exposure [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR43">43</xref>], while others considered BSA as the best predictor of CL<sub>5FU</sub> [<xref ref-type="bibr" rid="CR5">5</xref>]. In a PKPD study, principally aiming to describe hematological toxicity under a combination regimen with 5FU, neither BSA nor body weight were found to influence the variability in 5FU PK [<xref ref-type="bibr" rid="CR25">25</xref>]. Significant, but moderate, effects of either BSA [<xref ref-type="bibr" rid="CR3">3</xref>] or body weight [<xref ref-type="bibr" rid="CR44">44</xref>] on 5FU PK were confirmed in most population pharmacokinetic studies using nonlinear mixed-effect modelling. In the comparative covariate analysis, none of the indices representing body mass provided superiority over BSA regarding the improvement of model fit principally guided by reduction in OFV and % IIV. Patient&#8217;s gender was not found to influence CL<sub>5FU</sub> in the present study, which is consistent with a previous population pharmacokinetic analysis [<xref ref-type="bibr" rid="CR7">7</xref>]. Gender effect on CL<sub>5FU</sub> observed in some studies [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR41">41</xref>] might possibly be accounted for by differences in individual BSA. A considerably higher IIV of 145% was associated with <italic toggle="yes">V</italic><sub>c,5FU</sub> in comparison to previously reported values ranging from 19 to 114% [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. The CL<sub>5FUH2</sub> (126 L/h) and <italic toggle="yes">V</italic><sub>C,5FUH2</sub> (91.9 L) estimates in our study were comparable to those reported by Mueller et al. [<xref ref-type="bibr" rid="CR6">6</xref>]. An 18% higher CL<sub>5FUH2</sub> in men was reported, but the gender influence is not supported by the present evaluation, probably because of the lower proportion of female patients in the studied population. It is worth mentioning that exploratory covariate analyses in small- to medium-sized studies are expected to result in different sets of covariates, especially in case the covariates demonstrate moderate to high correlation such as body size, age, sex, and creatinine clearance.</p><p id="Par32">The effect of the <italic toggle="yes">MTHFR</italic> C677T mutation on CL<sub>5FU</sub> was found to be statistically significant. Population estimates for total clearance were 278 L/h (<italic toggle="yes">MTHFR</italic> 677CT or 677CC genotype) and 150 L/h (<italic toggle="yes">MTHFR</italic> 677TT genotype), but the genotype effect was not made part of the model due to lack of mechanistic plausibility as a predictor of 5FU PK. Published studies analysed this mutation primarily in relationship with 5FU efficacy and showed its favourable role in treatment response [<xref ref-type="bibr" rid="CR45">45</xref>] and survival [<xref ref-type="bibr" rid="CR46">46</xref>], considering the <italic toggle="yes">MTHFR</italic> genotype as an important predictor for the therapeutic effect of 5FU [<xref ref-type="bibr" rid="CR47">47</xref>]. The common C677T polymorphism in the <italic toggle="yes">MTHFR</italic> gene results in a considerably lower enzyme activity [<xref ref-type="bibr" rid="CR46">46</xref>] that probably increases intracellular folate concentrations, making tumors exhibiting mutated <italic toggle="yes">MTHFR</italic> genotypes more sensitive to cytotoxicity than wild-type <italic toggle="yes">MTHFR</italic> tumors [<xref ref-type="bibr" rid="CR48">48</xref>], if there are no differences in <italic toggle="yes">MTHFR</italic> genotype between tumor and somatic cells of the patient. It is difficult to deduce plausible mechanisms describing the influence of <italic toggle="yes">MTHFR</italic> on CL<sub>5FU</sub> based on the current knowledge on the metabolic pathways which provides a motivation to investigate this effect in further studies.</p><p id="Par33">The Friberg model [<xref ref-type="bibr" rid="CR24">24</xref>] is the standard approach to study the myelotoxicity under antineoplastic treatment. The model was originally developed using total WBC count data from rats treated with 5FU. A subsequent study comprised of a number of myelosuppression models demonstrated parameter consistency across different drugs [<xref ref-type="bibr" rid="CR49">49</xref>]. The developed models performed adequately to predict the time course of myelosuppression using both neutrophil and total leukocyte count data separately. The semi-mechanistic myelosuppression model appropriately described the total WBC count over time after 5FU administration. Transit compartments accounted for a delay between drug administration and the observed effect. Self-renewal/mitosis in the proliferating cells compartment was dependent on the number of cells, a rate constant for cell division (<italic toggle="yes">k</italic><sub>prol</sub>), and a feedback mechanism from the circulating cells (Circ<sub>0</sub>/Circ)<sup><italic toggle="yes">&#947;</italic></sup> which describes the rebound of cells as the proliferation rate is regulated by endogenous growth factors and cytokines [<xref ref-type="bibr" rid="CR50">50</xref>]. An estimate of 6.86&#8201;&#215;&#8201;10<sup>9</sup>/L for baseline leukocyte count (Circ<sub>0</sub>) was in the expected range [<xref ref-type="bibr" rid="CR22">22</xref>]. The Parameter estimates for <italic toggle="yes">&#947;</italic> (indicative of hematopoietic viability) were highly inconsistent across model runs; therefore, the value representative of a typical population was fixed according to the available literature [<xref ref-type="bibr" rid="CR22">22</xref>] to avoid an overshoot compared to Circ<sub>0</sub>. Myelosuppression was found to be significantly higher in patients receiving additional cisplatin (slope&#8201;=&#8201;2.82&#160;L/mg) as compared to the patients undergoing monotherapy (slope&#8201;=&#8201;1.17&#160;L/mg). In an attempt using a semi-physiological model to describe the relationship between the PK and the myelotoxicity contributed by respective components of the combination regimen comprised of 5FU, epirubicin and cyclophosphamide, the authors assumed negligible contribution by 5FU as it was not possible to estimate the effect contributed by 5FU and cyclophosphamide simultaneously [<xref ref-type="bibr" rid="CR25">25</xref>]. The hypotheses underlying this strong assumption was a lower hematological toxicity observed with continuous infusions as compared to 5FU bolus administration [<xref ref-type="bibr" rid="CR51">51</xref>], and a relatively stronger myelosuppression previously reported with epirubicin and cyclophosphamide in comparison to 5FU in rats [<xref ref-type="bibr" rid="CR52">52</xref>]. When 5FU is investigated alone, the present results demonstrate a significant amount of myelosuppression related to 5FU continuous infusion with WBC<sub>nadir</sub> values of 2.26 (&#215;&#8201;10<sup>9</sup>) and 4.29 (&#215;&#8201;10<sup>9</sup>) in patients receiving 5FU<sub>comb</sub> and 5FU<sub>mono</sub> regimens, respectively. <italic toggle="yes">T</italic><sub>nadir</sub> is typically expected between day 9 and day 14 with 5FU; however, the simulated <italic toggle="yes">T</italic><sub>nadir</sub> in the present study was observed between day 22 and day 25 after start (=&#8201;17&#8211;20&#160;days after end) of infusion, which may possibly be attributed to the continuous nature of the infusion.</p><p id="Par34">A comparative evaluation of the theoretical contribution of a 5FU dose to myelosuppression expectedly predicted a more pronounced effect for the higher dose administered in the FOLFIRINOX regimen in comparison to de Gramont regimen. Although, hematological toxicities in case of combination-based regimens are often additive in nature [<xref ref-type="bibr" rid="CR52">52</xref>&#8211;<xref ref-type="bibr" rid="CR55">55</xref>], a true prediction of the time course of myelosuppression under these therapeutic regimens may demand the incorporation of the effect of the other components, especially leucovorin, as one may expect differences in WBC<sub>nadir</sub> and <italic toggle="yes">T</italic><sub>nadir</sub>. Nevertheless, the simulations nicely show that just the FU component of even a single treatment course would put a considerable fraction of patients at risk for infections, as these doses are repeated every other week. Model-based prediction of WBC<sub>nadir</sub> and <italic toggle="yes">T</italic><sub>nadir</sub> along with monitoring during the course of treatment can be imperative for suitable sampling schedules, assessment of the patient&#8217;s immune competence, and the expected consequence of additional treatment cycles [<xref ref-type="bibr" rid="CR23">23</xref>]. Thus, it would be interesting to develop myelotoxicity models for 5-FU incorporating the effect of leucovorin in present regimens. Predictions may further be useful to identify patients or patient subgroups at a higher risk of toxicity.</p></sec><sec id="Sec20"><title>Conclusions</title><p id="Par35">A semi-physiological PKPD model of 5FU is presented. IIV in the CL<sub>5FU</sub> was partially explained by individual BSA. Frequent leukocyte count monitoring and model-based predictions may be used to take the contribution of 5FU to myelosuppression into account, especially in case of polychemotherapy regimens.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec21"><p>Below is the link to the electronic supplementary material.
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2019_4028_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file1 (PDF 969 kb)</p></caption></media></supplementary-material></p></sec></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Usman Arshad and Su-arpa Ploylearmsaeng equally contributed to this work.</p></fn><fn><p>Alexander Jetter and Max Taubert equally contributed to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Open Access funding provided by Projekt DEAL. The authors are thankful to all the patients and their families for their contribution. The study was supported by a Ph.D. scholarship (to UA) from the Higher Education Commission, Pakistan, in collaboration with the German Academic Exchange Service, Germany.</p></ack><notes notes-type="ethics"><title>Compliance with ethical standards</title><notes notes-type="COI-statement"><title>Conflict of interest</title><p id="Par36">The authors declare that there is no conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capitain</surname><given-names>O</given-names></name><name name-style="western"><surname>Boisdron-Celle</surname><given-names>M</given-names></name><name name-style="western"><surname>Poirier</surname><given-names>A-L</given-names></name><etal/></person-group><article-title>The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer</article-title><source>Pharmacogenom J</source><year>2008</year><volume>8</volume><fpage>256</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1038/sj.tpj.6500476</pub-id><pub-id pub-id-type="pmid">17700593</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kosmas</surname><given-names>C</given-names></name><name name-style="western"><surname>Kallistratos</surname><given-names>MS</given-names></name><name name-style="western"><surname>Kopterides</surname><given-names>P</given-names></name><etal/></person-group><article-title>Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study</article-title><source>J Cancer Res Clin Oncol</source><year>2007</year><volume>134</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1007/s00432-007-0250-9</pub-id><pub-id pub-id-type="pmid">17636329</pub-id><pub-id pub-id-type="pmcid">PMC12161746</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terret</surname><given-names>C</given-names></name><name name-style="western"><surname>Erdociain</surname><given-names>E</given-names></name><name name-style="western"><surname>Guimbaud</surname><given-names>R</given-names></name><etal/></person-group><article-title>Dose and time dependencies of 5-fluorouracil pharmacokinetics</article-title><source>Clin Pharmacol Ther</source><year>2000</year><volume>68</volume><fpage>270</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1067/mcp.2000.109352</pub-id><pub-id pub-id-type="pmid">11014408</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Beumer</surname><given-names>JH</given-names></name><name name-style="western"><surname>Chu</surname><given-names>E</given-names></name></person-group><article-title>Therapeutic drug monitoring of 5-fluorouracil</article-title><source>Cancer Chemother Pharmacol</source><year>2016</year><volume>78</volume><fpage>447</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1007/s00280-016-3054-2</pub-id><pub-id pub-id-type="pmid">27217046</pub-id><pub-id pub-id-type="pmcid">PMC5204259</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Port</surname><given-names>RE</given-names></name><name name-style="western"><surname>Daniel</surname><given-names>B</given-names></name><name name-style="western"><surname>Ding</surname><given-names>RW</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>R</given-names></name></person-group><article-title>Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance</article-title><source>Oncology</source><year>1991</year><volume>48</volume><fpage>277</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1159/000226942</pub-id><pub-id pub-id-type="pmid">1891168</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mueller</surname><given-names>F</given-names></name><name name-style="western"><surname>B&#252;chel</surname><given-names>B</given-names></name><name name-style="western"><surname>K&#246;berle</surname><given-names>D</given-names></name><etal/></person-group><article-title>Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study</article-title><source>Cancer Chemother Pharmacol</source><year>2013</year><volume>71</volume><fpage>361</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1007/s00280-012-2018-4</pub-id><pub-id pub-id-type="pmid">23139054</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Etienne</surname><given-names>M-C</given-names></name><name name-style="western"><surname>Chatelut</surname><given-names>E</given-names></name><name name-style="western"><surname>Pivot</surname><given-names>X</given-names></name><etal/></person-group><article-title>Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis</article-title><source>Eur J Cancer</source><year>1998</year><volume>34</volume><fpage>92</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(97)00345-6</pub-id><pub-id pub-id-type="pmid">9624244</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bouch&#233;</surname><given-names>O</given-names></name><name name-style="western"><surname>Laurent-Puig</surname><given-names>P</given-names></name><name name-style="western"><surname>Boisdron-Celle</surname><given-names>M</given-names></name><etal/></person-group><article-title>5-fluorouracile: MSI, pharmacocin&#233;tique, DPD, TYMS et MTHFR</article-title><source>M&#233;decine Personnal en canc&#233;rologie Dig</source><year>2013</year><pub-id pub-id-type="doi">10.1007/978-2-8178-0527-6_6</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diasio</surname><given-names>RB</given-names></name><name name-style="western"><surname>Harris</surname><given-names>BE</given-names></name></person-group><article-title>Clinical Pharmacology of 5-Fluorouracil</article-title><source>Clin Pharmacokinet</source><year>1989</year><volume>16</volume><fpage>215</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.2165/00003088-198916040-00002</pub-id><pub-id pub-id-type="pmid">2656050</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Kuilenburg</surname><given-names>AB</given-names></name></person-group><article-title>Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil</article-title><source>Eur J Cancer</source><year>2004</year><volume>40</volume><fpage>939</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1016/J.EJCA.2003.12.004</pub-id><pub-id pub-id-type="pmid">15093568</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>K&#246;hne</surname><given-names>CH</given-names></name><name name-style="western"><surname>Peters</surname><given-names>GJ</given-names></name></person-group><article-title>UFT: Mechanism of drug action</article-title><source>Oncology</source><year>2000</year><volume>14</volume><fpage>13</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1201/9781315383293-2</pub-id><pub-id pub-id-type="pmid">11098484</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pullarkat</surname><given-names>ST</given-names></name><name name-style="western"><surname>Lenz</surname><given-names>HJ</given-names></name></person-group><article-title>Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy</article-title><source>Pharmacogenom J</source><year>2001</year><volume>1</volume><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1038/sj.tpj.6500012</pub-id><pub-id pub-id-type="pmid">11913730</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Etienne-Grimaldi</surname><given-names>M-C</given-names></name><name name-style="western"><surname>Francoual</surname><given-names>M</given-names></name><name name-style="western"><surname>Formento</surname><given-names>J-L</given-names></name><name name-style="western"><surname>Milano</surname><given-names>G</given-names></name></person-group><article-title>Methylenetetrahydrofolate reductase (<italic toggle="yes">MTHFR</italic>) variants and fluorouracil-based treatments in colorectal cancer</article-title><source>Pharmacogenomics</source><year>2007</year><volume>8</volume><fpage>1561</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.2217/14622416.8.11.1561</pub-id><pub-id pub-id-type="pmid">18034621</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deyme</surname><given-names>L</given-names></name><name name-style="western"><surname>Barbolosi</surname><given-names>D</given-names></name><name name-style="western"><surname>Gattacceca</surname><given-names>F</given-names></name></person-group><article-title>Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters</article-title><source>Cancer Chemother Pharmacol</source><year>2018</year><volume>83</volume><fpage>27</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1007/s00280-018-3722-5</pub-id><pub-id pub-id-type="pmid">30446786</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanna</surname><given-names>CL</given-names></name><name name-style="western"><surname>McKinna</surname><given-names>FE</given-names></name><name name-style="western"><surname>Williams</surname><given-names>LB</given-names></name><etal/></person-group><article-title>High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients</article-title><source>Br J Cancer</source><year>1995</year><volume>72</volume><fpage>774</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1038/bjc.1995.409</pub-id><pub-id pub-id-type="pmid">7669593</pub-id><pub-id pub-id-type="pmcid">PMC2033907</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tepper</surname><given-names>J</given-names></name><name name-style="western"><surname>Krasna</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Niedzwiecki</surname><given-names>D</given-names></name><etal/></person-group><article-title>Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>1086</fpage><lpage>1092</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.12.9593</pub-id><pub-id pub-id-type="pmid">18309943</pub-id><pub-id pub-id-type="pmcid">PMC5126644</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meulendijks</surname><given-names>D</given-names></name><name name-style="western"><surname>Henricks</surname><given-names>LM</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>BAW</given-names></name><etal/></person-group><article-title>Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity</article-title><source>Br J Cancer</source><year>2017</year><volume>116</volume><fpage>1415</fpage><lpage>1424</lpage><pub-id pub-id-type="doi">10.1038/bjc.2017.94</pub-id><pub-id pub-id-type="pmid">28427087</pub-id><pub-id pub-id-type="pmcid">PMC5520099</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garg</surname><given-names>MB</given-names></name><name name-style="western"><surname>Lincz</surname><given-names>LF</given-names></name><name name-style="western"><surname>Adler</surname><given-names>K</given-names></name><etal/></person-group><article-title>Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis</article-title><source>Br J Cancer</source><year>2012</year><volume>107</volume><fpage>1525</fpage><lpage>1533</lpage><pub-id pub-id-type="doi">10.1038/bjc.2012.421</pub-id><pub-id pub-id-type="pmid">22990653</pub-id><pub-id pub-id-type="pmcid">PMC3493765</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macdonald</surname><given-names>JS</given-names></name></person-group><article-title>Toxicity of 5-fluorouracil</article-title><source>Oncology (Williston Park)</source><year>1999</year><volume>13</volume><fpage>33</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">10442356</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alnaim</surname><given-names>L</given-names></name></person-group><article-title>Individualization of 5-fluorouracil in the treatment of colorectal cancer</article-title><source>SRX Pharmacol</source><year>2010</year><volume>2010</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.3814/2010/352491</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilhelm</surname><given-names>M</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>L</given-names></name><name name-style="western"><surname>Miller</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Prospective, multicenter study of 5-fluorouracil therapeutic drug monitoring in metastatic colorectal cancer treated in routine clinical practice</article-title><source>Clin Colorectal Cancer</source><year>2016</year><volume>15</volume><fpage>381</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1016/j.clcc.2016.04.001</pub-id><pub-id pub-id-type="pmid">27256667</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soto</surname><given-names>E</given-names></name><name name-style="western"><surname>Keizer</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Troc&#243;niz</surname><given-names>IF</given-names></name><etal/></person-group><article-title>Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies</article-title><source>Investig New Drugs</source><year>2011</year><volume>29</volume><fpage>984</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1007/s10637-010-9437-z</pub-id><pub-id pub-id-type="pmid">20449627</pub-id><pub-id pub-id-type="pmcid">PMC3160557</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Netterberg</surname><given-names>I</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>EI</given-names></name><name name-style="western"><surname>Friberg</surname><given-names>LE</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></name></person-group><article-title>Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring</article-title><source>Cancer Chemother Pharmacol</source><year>2017</year><volume>80</volume><fpage>343</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1007/s00280-017-3366-x</pub-id><pub-id pub-id-type="pmid">28656382</pub-id><pub-id pub-id-type="pmcid">PMC5532422</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friberg</surname><given-names>LE</given-names></name><name name-style="western"><surname>Freijs</surname><given-names>A</given-names></name><name name-style="western"><surname>Sandstrom</surname><given-names>M</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></name></person-group><article-title>Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats</article-title><source>J Pharmacol Exp Ther</source><year>2000</year><volume>295</volume><fpage>734</fpage><lpage>740</lpage><pub-id pub-id-type="pmid">11046112</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sandstr&#246;m</surname><given-names>M</given-names></name><name name-style="western"><surname>Lindman</surname><given-names>H</given-names></name><name name-style="western"><surname>Nygren</surname><given-names>P</given-names></name><etal/></person-group><article-title>Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients</article-title><source>Cancer Chemother Pharmacol</source><year>2006</year><volume>58</volume><fpage>143</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1007/s00280-005-0140-2</pub-id><pub-id pub-id-type="pmid">16465545</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">The Declaration of Helsinki, as established by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended by the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Fortaleza (Brazil)</mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">German Drug Act (Arzneimittelgesetz). Applicable version: Elftes Gesetz zur &#196;nderung des Arzneimittelgesetzes vom 21. August 2002/BGBl. I, S. 3348. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gesetze-im-internet.de/amg_1976/">https://www.gesetze-im-internet.de/amg_1976/</ext-link>. Accessed 2 Nov 2019</mixed-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazar</surname><given-names>A</given-names></name><name name-style="western"><surname>Mau-Holzmann</surname><given-names>UA</given-names></name><name name-style="western"><surname>Kolb</surname><given-names>H</given-names></name><etal/></person-group><article-title>Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant</article-title><source>Oncol Res Treat</source><year>2004</year><volume>27</volume><fpage>559</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1159/000081338</pub-id><pub-id pub-id-type="pmid">15591715</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iacopetta</surname><given-names>B</given-names></name><name name-style="western"><surname>Grieu</surname><given-names>F</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>D</given-names></name><name name-style="western"><surname>Elsaleh</surname><given-names>H</given-names></name></person-group><article-title>A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil</article-title><source>Br J Cancer</source><year>2001</year><volume>85</volume><fpage>827</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1054/bjoc.2001.2007</pub-id><pub-id pub-id-type="pmid">11556832</pub-id><pub-id pub-id-type="pmcid">PMC2375084</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shrubsole</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y-T</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Q</given-names></name><etal/></person-group><article-title>MTHFR polymorphisms, dietary folate intake, and breast cancer risk: results from the Shanghai Breast Cancer Study</article-title><source>Cancer Epidemiol Biomark Prev</source><year>2004</year><volume>13</volume><fpage>190</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.epi-03-0273</pub-id><pub-id pub-id-type="pmid">14973091</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">R Core Team (2018) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.R-project.org/">https://www.R-project.org/</ext-link></mixed-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Beal</surname><given-names>SL</given-names></name><name name-style="western"><surname>Sheiner</surname><given-names>LB</given-names></name></person-group><article-title>Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance</article-title><source>J Pharmacokinet Pharmacodyn</source><year>2003</year><volume>30</volume><fpage>387</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1023/B:JOPA.0000012998.04442.1f</pub-id><pub-id pub-id-type="pmid">15000421</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindbom</surname><given-names>L</given-names></name><name name-style="western"><surname>Ribbing</surname><given-names>J</given-names></name><name name-style="western"><surname>Jonsson</surname><given-names>EN</given-names></name></person-group><article-title>Perl-speaks-NONMEM (PsN)&#8212;a Perl module for NONMEM related programming</article-title><source>Comput Methods Progr Biomed</source><year>2004</year><volume>75</volume><fpage>85</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.cmpb.2003.11.003</pub-id><pub-id pub-id-type="pmid">15212851</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ezzeldin</surname><given-names>H</given-names></name><name name-style="western"><surname>Diasio</surname><given-names>R</given-names></name></person-group><article-title>Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration</article-title><source>Clin Colorectal Cancer</source><year>2004</year><volume>4</volume><fpage>181</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.3816/ccc.2004.n.018</pub-id><pub-id pub-id-type="pmid">15377401</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Kuilenburg</surname><given-names>ABP</given-names></name><name name-style="western"><surname>Muller</surname><given-names>EW</given-names></name><name name-style="western"><surname>Haasjes</surname><given-names>J</given-names></name><etal/></person-group><article-title>Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: Frequency of the common IVS14+1G%3eA mutation causing DPD deficiency</article-title><source>Clin Cancer Res</source><year>2001</year><volume>7</volume><fpage>1149</fpage><lpage>1153</lpage><pub-id pub-id-type="pmid">11350878</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seck</surname><given-names>K</given-names></name><name name-style="western"><surname>Riemer</surname><given-names>S</given-names></name><name name-style="western"><surname>Kates</surname><given-names>R</given-names></name><etal/></person-group><article-title>Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>5886</fpage><lpage>5892</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-1784</pub-id><pub-id pub-id-type="pmid">16115930</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ploylearmsaeng</surname><given-names>S</given-names></name><name name-style="western"><surname>Fuhr</surname><given-names>U</given-names></name><name name-style="western"><surname>Jetter</surname><given-names>A</given-names></name></person-group><article-title>How may anticancer chemotherapy with fluorouracil be individualised?</article-title><source>Clin Pharmacokinet</source><year>2006</year><volume>45</volume><fpage>567</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.2165/00003088-200645060-00002</pub-id><pub-id pub-id-type="pmid">16719540</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porta-Oltra</surname><given-names>B</given-names></name><name name-style="western"><surname>P&#233;rez-Ruixo</surname><given-names>J</given-names></name><name name-style="western"><surname>Climente-Mart&#237;</surname><given-names>M</given-names></name><etal/></person-group><article-title>Population pharmacokinetics of 5-fluorouracil in colorectal cancer patients</article-title><source>J Oncol Pharm Pract</source><year>2004</year><volume>10</volume><fpage>155</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1191/1078155204jp129oa</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woloch</surname><given-names>C</given-names></name><name name-style="western"><surname>Di Paolo</surname><given-names>A</given-names></name><name name-style="western"><surname>Marouani</surname><given-names>H</given-names></name><etal/></person-group><article-title>Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity</article-title><source>Curr Top Med Chem</source><year>2012</year><volume>12</volume><fpage>1713</fpage><lpage>1719</lpage><pub-id pub-id-type="doi">10.2174/156802612803531414</pub-id><pub-id pub-id-type="pmid">22978343</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bressolle</surname><given-names>F</given-names></name><name name-style="western"><surname>Joulia</surname><given-names>JM</given-names></name><name name-style="western"><surname>Pinguet</surname><given-names>F</given-names></name><etal/></person-group><article-title>Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer</article-title><source>Cancer Chemother Pharmacol</source><year>1999</year><volume>44</volume><fpage>295</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1007/s002800050980</pub-id><pub-id pub-id-type="pmid">10447576</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Kuilenburg</surname><given-names>ABP</given-names></name><name name-style="western"><surname>H&#228;usler</surname><given-names>P</given-names></name><name name-style="western"><surname>Schalhorn</surname><given-names>A</given-names></name><etal/></person-group><article-title>Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a C. 1905+1G%3eA mutation in DPYD by means of a Bayesian Limited sampling strategy</article-title><source>Clin Pharmacokinet</source><year>2012</year><volume>51</volume><fpage>163</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1007/BF03257473</pub-id><pub-id pub-id-type="pmid">22339448</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fleming</surname><given-names>RA</given-names></name><name name-style="western"><surname>Milano</surname><given-names>GA</given-names></name><name name-style="western"><surname>Etienne</surname><given-names>MC</given-names></name><etal/></person-group><article-title>No effect of dose, hepatic function, or nutritional status on 5-fu clearance following continuous (5-day), 5-fu infusion</article-title><source>Br J Cancer</source><year>1992</year><volume>66</volume><fpage>668</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1038/bjc.1992.335</pub-id><pub-id pub-id-type="pmid">1419604</pub-id><pub-id pub-id-type="pmcid">PMC1977433</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grem</surname><given-names>JL</given-names></name><name name-style="western"><surname>McAtee</surname><given-names>N</given-names></name><name name-style="western"><surname>Balis</surname><given-names>F</given-names></name><etal/></person-group><article-title>A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma</article-title><source>Cancer</source><year>1993</year><volume>72</volume><fpage>663</fpage><lpage>668</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0142(19930801)72:3&amp;#x0003c;663::AID-CNCR2820720307&amp;#x0003e;3.0.CO;2-V</pub-id><pub-id pub-id-type="pmid">8334622</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Climente-Mart&#237;</surname><given-names>M</given-names></name><name name-style="western"><surname>Merino-Sanju&#225;n</surname><given-names>M</given-names></name><name name-style="western"><surname>Almenar-Cubells</surname><given-names>D</given-names></name><name name-style="western"><surname>Jim&#233;nez-Torres</surname><given-names>NV</given-names></name></person-group><article-title>A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer</article-title><source>J Pharm Sci</source><year>2003</year><volume>92</volume><fpage>1155</fpage><lpage>1165</lpage><pub-id pub-id-type="doi">10.1002/JPS.10374</pub-id><pub-id pub-id-type="pmid">12761805</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Etienne-Grimaldi</surname><given-names>M-C</given-names></name><name name-style="western"><surname>Milano</surname><given-names>G</given-names></name><name name-style="western"><surname>Maindrault-Goebel</surname><given-names>F</given-names></name><etal/></person-group><article-title>Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients</article-title><source>Br J Clin Pharmacol</source><year>2010</year><volume>69</volume><fpage>58</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2009.03556.x</pub-id><pub-id pub-id-type="pmid">20078613</pub-id><pub-id pub-id-type="pmcid">PMC2830598</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Etienne</surname><given-names>MC</given-names></name><name name-style="western"><surname>Formento</surname><given-names>JL</given-names></name><name name-style="western"><surname>Chazal</surname><given-names>M</given-names></name><etal/></person-group><article-title>Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients</article-title><source>Pharmacogenetics</source><year>2004</year><volume>14</volume><fpage>785</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1097/00008571-200412000-00001</pub-id><pub-id pub-id-type="pmid">15608557</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwab</surname><given-names>M</given-names></name><name name-style="western"><surname>Zanger</surname><given-names>UM</given-names></name><name name-style="western"><surname>Marx</surname><given-names>C</given-names></name><etal/></person-group><article-title>Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>2131</fpage><lpage>2138</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.10.4182</pub-id><pub-id pub-id-type="pmid">18299612</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gusella</surname><given-names>M</given-names></name><name name-style="western"><surname>Ferrazzi</surname><given-names>E</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>M</given-names></name><name name-style="western"><surname>Padrini</surname><given-names>R</given-names></name></person-group><article-title>New limited sampling strategy for determining 5-fluorouracil area under the concentration-time curve after rapid intravenous bolus</article-title><source>Ther Drug Monit</source><year>2002</year><volume>24</volume><fpage>425</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1097/00007691-200206000-00016</pub-id><pub-id pub-id-type="pmid">12021636</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friberg</surname><given-names>LE</given-names></name><name name-style="western"><surname>Henningsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Maas</surname><given-names>H</given-names></name><etal/></person-group><article-title>Model of chemotherapy-induced myelosuppression with parameter consistency across drugs</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>4713</fpage><lpage>4721</lpage><pub-id pub-id-type="doi">10.1200/JCO.2002.02.140</pub-id><pub-id pub-id-type="pmid">12488418</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takatani</surname><given-names>H</given-names></name><name name-style="western"><surname>Soda</surname><given-names>H</given-names></name><name name-style="western"><surname>Fukuda</surname><given-names>M</given-names></name><etal/></person-group><article-title>Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts</article-title><source>Antimicrob Agents Chemother</source><year>1996</year><volume>40</volume><fpage>988</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.1128/aac.40.4.988</pub-id><pub-id pub-id-type="pmid">8849265</pub-id><pub-id pub-id-type="pmcid">PMC163244</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>RM</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>L</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>T</given-names></name><etal/></person-group><article-title>Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer</article-title><source>J Natl Cancer Inst</source><year>1996</year><volume>88</volume><fpage>668</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1093/jnci/88.10.668</pub-id><pub-id pub-id-type="pmid">8627643</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Brulin</surname><given-names>EA</given-names></name><name name-style="western"><surname>Driessen</surname><given-names>OMJ</given-names></name><name name-style="western"><surname>Hermans</surname><given-names>J</given-names></name></person-group><article-title>The CMF-regimen. Toxicity patterns following stepwise combinations of cyclophosphamide, methotrexate and fluorouracil</article-title><source>Int J Cancer</source><year>1991</year><volume>48</volume><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1002/ijc.2910480113</pub-id><pub-id pub-id-type="pmid">2019458</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sandstr&#246;m</surname><given-names>M</given-names></name><name name-style="western"><surname>Lindman</surname><given-names>H</given-names></name><name name-style="western"><surname>Nygren</surname><given-names>P</given-names></name><etal/></person-group><article-title>Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>413</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.09.161</pub-id><pub-id pub-id-type="pmid">15585753</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zandvliet</surname><given-names>AS</given-names></name><name name-style="western"><surname>Schellens</surname><given-names>JHM</given-names></name><name name-style="western"><surname>Dittrich</surname><given-names>C</given-names></name><etal/></person-group><article-title>Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin</article-title><source>Br J Clin Pharmacol</source><year>2008</year><volume>66</volume><fpage>485</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2008.03230.x</pub-id><pub-id pub-id-type="pmid">18637887</pub-id><pub-id pub-id-type="pmcid">PMC2561111</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zandvliet</surname><given-names>AS</given-names></name><name name-style="western"><surname>Siegel-Lakhai</surname><given-names>WS</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>JH</given-names></name><etal/></person-group><article-title>PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression</article-title><source>Clin Pharmacol Ther</source><year>2008</year><volume>83</volume><fpage>829</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1038/sj.clpt.6100344</pub-id><pub-id pub-id-type="pmid">17851564</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>